5-(4-chloro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester | 864426-74-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-chloro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester
• 英文别名: ethyl 5-(4-chlorophenyl)-1,4-dimethylpyrazole-3-carboxylate
• CAS: 864426-74-4
• 化学式: C₁₄H₁₅ClN₂O₂
• 分子量: 278.738
• InChiKey: IQKDDCQLRHQXTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氨基-6-甲基吡啶 、 5-(4-chloro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester 在 三甲基铝 作用下， 以 1,4-二氧六环 、 甲苯 为溶剂， 生成 5-(4-chlorophenyl)-1,4-dimethyl-N-(6-methylpyridin-2-yl)pyrazole-3-carboxamide
  参考文献：
  名称：

  Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators

  摘要：

  Development of SAR in a 5-aryl-3-acylpyridinyl-pyrazoles and 1-aryl-4-acylpyridinyl imidazoles series of mGlu5 receptor negative allosteric modulators (mGluR5 NAMs) using a functional cell-based assay is described in this Letter. Analysis of the Ligand-lipophilic efficiency (LipE) of compounds provided new insight for the design of potent mGluR5 negative allosteric modulators with anti-depressant activities. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.116
• 作为产物：
  描述：

  4-氯苯丙酮 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 5-(4-chloro-phenyl)-1,4-dimethyl-1H-pyrazole-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators

  摘要：

  Development of SAR in a 5-aryl-3-acylpyridinyl-pyrazoles and 1-aryl-4-acylpyridinyl imidazoles series of mGlu5 receptor negative allosteric modulators (mGluR5 NAMs) using a functional cell-based assay is described in this Letter. Analysis of the Ligand-lipophilic efficiency (LipE) of compounds provided new insight for the design of potent mGluR5 negative allosteric modulators with anti-depressant activities. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.01.116

文献信息

• Indolyl derivatives
  申请人：Ackermann Jean

  公开号：US20050203160A1

  公开（公告）日：2005-09-15

  This invention relates to compounds of the formula I: wherein one of R 6 , R 7 and R 8 is and R 1 to R 15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPAR δ and/or PPARα agonists.

  这项发明涉及式I的化合物：其中R6、R7和R8中的一个是R1至R15和n如描述中所定义的，以及其所有对映体和药用盐和/或酯。该发明还涉及含有这种化合物的药物组合物，以及用于治疗和/或预防由PPAR δ和/或PPARα激动剂调节的疾病的方法。
• PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS
  申请人：F.HOFFMANN-LA ROCHE AG

  公开号：EP1725546A1

  公开（公告）日：2006-11-29
• EP1725546B1
  申请人：——

  公开号：EP1725546B1

  公开（公告）日：2008-10-08
• US7265149B2
  申请人：——

  公开号：US7265149B2

  公开（公告）日：2007-09-04
• [EN] PYRAZOLYL INDOLYL DERIVATIVES AS PPAR ACTIVATORS<br/>[FR] DERIVES DE PYRAZOLYL-INDOLYLE UTILISES COMME ACTIVATEURS DE PPAR
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005085235A1

  公开（公告）日：2005-09-15

  This invention is concerned with compounds of the formula (I), wherein one of R6, R7 and R8 is (II), and R1 to R15 and n are as defined in the description, and all enantiomers and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are modulated by PPARδ and/or PPARα agonists.